ABSTRACT
Psychiatric disorders are notoriously heterogenous, often rendering diagnostic efforts challenging, and leading to poor therapeutic outcomes. The growing emphasis on ‘transdiagnostic’ approaches in psychiatry aligns well with the National Institute of Health-devised Research Domain Criteria (RDoc) framework that seeks to enable precision psychiatry. Here, we sought to identify transdiagnostic subgroups, which share behavioral and neural abnormalities, in a large population of psychiatric inpatients treated at a tertiary psychiatric hospital. The sample included 1,571 patients across five units within the Depression & Anxiety Disorders Division at McLean Hospital who completed self-assessments as part of an ongoing quality-of-care improvement project. Self-assessments included validated measures of depression, anxiety, anhedonia, trauma exposure, personality traits and substance misuse as well as broader screening questions. First, we identified naturally occurring transdiagnostic subgroups based on the self-reported questionnaires using consensus clustering to implement partition-around-medoids. In a subsample, we ascertained brain functional connectivity differences between the resultant subgroups using a multi-granular approach, i.e. whole-brain to connection-wise. In a k=2 partitioning solution, the first transdiagnostic cluster; C1 (N=809) had consistently higher means across all questionnaires compared to the second cluster; C2 (N=762). QIDS total score (P<0.0001, effect size = 0.54) and BASIS-24 derived total score (P<0.0001, effect size = 0.53) showed the largest difference between the groups. In follow-up imaging analysis (N=26) functional connectivity (FC) differences were observed connection-wise (P<0.0001) and between functional networks (P<0.0001), with C1 showing stronger FC than C2. Sex differences by cluster analyses revealed that females had higher BASIS-24 derived depression/functioning (C1: P<0.0001; C2: P<0.0001), and QIDS (C1|C2; P<0.0001 | P<0.0001) scores compared to males in both clusters. This was coupled with greater intermodular FC in males than females in C1 (P<0.0001) and C2 (P<0.0005). These results suggest that inpatients with transdiagnostic symptoms show biobehavioural abnormalities, underpinned by sex differences. Behaviourally, this is a function of acuity, i.e., severity of psychopathological symptoms, and not diagnosis. Biologically, the dysfunction captured here may span across various brain networks, rather than a singular region.
Competing Interest Statement
Over the past 3 years, DP has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sage Therapeutics, Sama Therapeutics, Sunovion Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. KJR has performed scientific consultation for Acer, Bionomics, and Jazz Pharma; serves on Scientific Advisory Boards for Sage, Boehringer Ingelheim, Senseye, Brain and Behavior Research Foundation and the Brain Research Foundation, and he has received sponsored research support from Alto Neuroscience. N.P.D. has been on scientific advisory boards for BioVie Inc., Circular Genomics, Inc., and Feel Therapeutics, Inc. for unrelated work. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors declare no competing interests
Funding Statement
This study was funded by an award from Wellcome Leap Inc., by the Wellcome Trust for the Multi-Channel Psychiatry (MC-Psych) programme 'Revealing Mechanisms of Anhedonia' awarded to DP, KJR and NPD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were approved by the Mass General Brigham Institutional Review Board (IRB), and all participants provided written informed consent, between January 2018 and November 2023 as part of the Clinical Measurement Initiative (CMI; IRB# 2021P002444), an ongoing patient care quality improvement/quality control (QI/QC) project.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Error in author metadata. Main article and supplemental materials updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
